Tarsus Pharmaceuticals, Inc. Common Stock
TARSStock
$57.69+41.70%52W
Market Cap$2.48B
P/E—
Div yield—
Beta0.51
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-35.82%
Price vs S&P 500 (4W)-6.02%
VGM Score53.16
Market Capitalization$2.48B
Earnings Surprise History
Q1 26-0.16est. -0.38
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.40
4.40
4.40
4.40
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TARSTarsus Pharmaceuticals, Inc. Common Stock | D | A | D | $57.69 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company developing first-in-class therapeutics for eye care. Its lead product, XDEMVY, is an investigational eye drop for treating Demodex blepharitis, with additional candidates in development for ocular rosacea and other ophthalmic conditions.